MARKET

CANF

CANF

Can Fite Biophar
AMEX
3.710
+0.190
+5.40%
After Hours: 3.850 +0.14 +3.77% 19:01 07/26 EDT
OPEN
3.560
PREV CLOSE
3.520
HIGH
3.863
LOW
3.500
VOLUME
133.25K
TURNOVER
0
52 WEEK HIGH
4.690
52 WEEK LOW
1.810
MARKET CAP
18.51M
P/E (TTM)
-2.0708
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CANF last week (0715-0719)?
Weekly Report · 4d ago
Can-Fite Biopharma Initiated at Buy by EF Hutton
Dow Jones · 07/17 12:38
Can-Fite Biopharma Price Target Announced at $10.00/Share by EF Hutton
Dow Jones · 07/17 12:38
EF Hutton Initiates Coverage On Can Fite Biofarma with Buy Rating, Announces Price Target of $10
Benzinga · 07/17 12:28
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
Can-Fite BioPharma Ltd. Invites investors to a webinar on August 8, 2024, at 4:15 p.m. ET. The company is a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases.
Barchart · 07/17 06:00
Weekly Report: what happened at CANF last week (0708-0712)?
Weekly Report · 07/15 09:32
Can-Fite Seeks FDA Nod for Cancer Drug Namodenoson
TipRanks · 07/11 11:27
Can-Fite Submits Application To FDA For Orphan Drug Designation For Its Drug Candidate Namodenoson In The Treatment Of Pancreatic Carcinoma
Can-Fite plans to start a Phase IIa clinical study in patients with advanced pancreatic cancer. Namodenoson has already been granted Orphan Drug Status for the indication of advanced liver cancer by the FDA and EMA. The trial will evaluate the safety, clinical activity and pharmacokinetics of the drug.
Benzinga · 07/11 11:04
More
About CANF
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Webull offers Can Fite Biopharma Ltd stock information, including AMEX: CANF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CANF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CANF stock methods without spending real money on the virtual paper trading platform.